Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Results: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young a…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD22 CAR T cells in pediatric and young adult patients with recurrent or refractory CD22-expressing B-cell mal…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma [EARLY_Phase 1]
Early-phase clinical trial update on the safety, efficacy and metabolic kinetics of CT1182 injection in relapsed/refractory non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]
Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; …
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy [NA]
This clinical trial update reports completion of a study to identify immune-related biomarkers that predict the efficacy of cancer immunothe…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
A completed clinical trial update detailing a genome expression study in leukemia, multiple myeloma, and lymphomas (Hodgkin and Non-Hodgkin)…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers [Phase 2]
This clinical trial update summarizes long-term safety data for pirtobrutinib in participants with previously treated blood cancers from a P…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: First in Human, Dose Escalation, Dose Expansion Study of AUR105 [Phase 1]
AUR105 is Aurigene's first-in-human Phase 1 study with dose-escalation and dose-expansion cohorts in adults with solid tumors and lymphomas.…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating a two-step reduced-intensity conditioning approach for bone marrow transplant in adults with hematologic malignanci…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors [NA]
This completed clinical trial evaluated the effectiveness and implementation of an electronic health record tool to assess heart health amon…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) [Phase 2]
Phase 2 update from the Pediatric MATCH trial describes targeted therapies matched to tumor genetics in pediatric patients with relapsed or …
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial update. It evaluates a conditioning strategy using chemotherapy, total body irradiation, and post-transpl…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial of IPH6501 in relapsed/refractory B-cell non-Hodgkin lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Studying TAK-243 in Patients With Advanced Cancer [Phase 1]
This entry describes a Phase 1 clinical trial evaluating TAK-243 in adults with advanced cancers, including non-Hodgkin lymphoma and various…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring [Phase 1]
Phase 1 rollover study by Janssen Research & Development to continue study treatment and ongoing safety monitoring in patients with acute my…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial evaluating veliparib in combination with cyclophosphamide and doxorubicin hydrochloride for patients with metastatic …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer [Phase 1]
Phase 1 trial update for Janssen's JNJ-87801493 in combination with T-cell engagers for B-cell Non-Hodgkin lymphoma; the study is currently …
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma [Phase 1]
A Phase 1 dose-escalation and expansion study of CPO107 in patients with advanced CD20-positive non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]
This Phase 1 trial evaluated donor-derived anti-CD19 CAR-T cells in patients with recurrent or persistent B-cell malignancies after allogene…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT [Phase 1]
Phase 1 clinical trial update on DLI-X as a prophylactic and therapeutic donor lymphocyte infusion to prevent or treat leukemia relapse afte…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study [NA]
Completed clinical trial evaluating a geriatric optimization plan to improve survival in older adults undergoing allogeneic hematopoietic ce…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports on AB-101 as a monotherapy and in combination with immunotherapy for relapsed/refractory B-cell Non-Hodgk…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: 9-ING-41 in Patients With Advanced Cancers [Phase 2]
Actuate Therapeutics' Phase 2 trial of 9-ING-41 in patients with advanced cancers is currently active but not recruiting, with pancreatic ca…